RefleXion Announces Accretive Reimbursement for SCINTIX Therapy in Freestanding Cancer Centers

New payment rates expand patient access to autonomous radiotherapy

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, an external-beam theranostic oncology company, today announced that two Medicare Administrator Contractors (MACs) have established payment rates for SCINTIX® autonomous radiotherapy in freestanding centers (FSCs) that appropriately reflect the cost of delivering this advanced therapy. This decision allows physicians at FSCs to begin offering SCINTIX therapy as a new treatment option for patients with primary or metastatic lung or bone tumors.

“Accretive reimbursement is essential for enabling freestanding centers to adopt breakthrough technologies,” said Todd Powell, president and CEO at RefleXion. “By assigning sufficient payment for SCINTIX therapy, these MACs are recognizing both its innovation and the learning required, clearing the path for broader patient access.”

The MACs — Novitas Solutions and First Coast Service Options — collectively cover approximately 30 percent of the United States, including Arkansas, Colorado, Delaware, the District of Columbia, Florida, Louisiana, Maryland, New Jersey, New Mexico, Oklahoma, Pennsylvania, Texas, U.S. Caribbean territories, Indian Health Services, and the Veterans Health Administration.

About 40 percent of U.S. cancer patients receive radiation therapy in FSCs centers¹, thus establishing reimbursement for these settings is critical to removing financial barriers to adoption of innovative treatment options thereby improving patient access.

SCINTIX therapy includes a modeling procedure followed by up to five treatment sessions. The MACs assigned payment rates for the technical components of both procedures, and the professional component of the modeling procedure, which requires additional physician work. The professional payment also applies to procedures performed in the hospital outpatient department.

Earlier this month, the company announced U.S. Food and Drug Administration clearance of its next generation platform, the RefleXion® X2 with SCINTIX therapy. The X2 features wide field-of-view PET detector technology that quadruples the imaging field and increases sensitivity 20-fold, producing sharper images with less noise and improving visualization of moving tumors. By significantly increasing biological signal detection, the platform aims to expand the number of patients eligible for SCINTIX therapy.

About RefleXion Medical

RefleXion is a privately held theranostic oncology company located in Hayward, Calif., commercializing SCINTIX autonomous radiotherapy, that uses a single radiotracer injection to turn cancer cells into real-time biological beacons to guide external-beam radiotherapy. SCINTIX therapy is FDA-cleared for FDG-guided treatment of lung and bone tumors, including metastases. The RefleXion X2 platform is also cleared for conventional image-guided radiotherapy for solid tumors located anywhere in the body. For more information, visit www.reflexion.com.

¹ https://docs.house.gov/meetings/IF/IF14/20171108/106599/HHRG-115-IF14-Wstate-KavanaghB-20171108.pdf